Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.62 |
| ▸ | CTSS | P25774 | 3/20 | 0.62 |
| ▸ | CTSK | P43235 | 3/20 | 0.62 |
| ▸ | CTSH | P09668 | 1/20 | 0.62 |
| ▸ | IL23R | Q5VWK5 | 11/20 | 0.56 |
| ▸ | MC4R | P32245 | 4/20 | 0.55 |
| ▸ | MC5R | P33032 | 2/20 | 0.55 |
| ▸ | MC3R | P41968 | 2/20 | 0.55 |
| ▸ | MC1R | Q01726 | 2/20 | 0.55 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.54 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14552592 | 0.98 | CTSL (0.61) | CTSLCTSSCTSKCTSHIL23R | |
| SCHEMBL14552163 | 0.96 | CTSL (0.59) | CTSLCTSSCTSKCTSHIL23R | |
| SCHEMBL14552164 | 0.94 | CTSL (0.65) | CTSLCTSSCTSKCTSHIL23R | |
| SCHEMBL14552136 | 0.92 | CTSL (0.54) | CTSLCTSSCTSKCTSHIL23R | |
| SCHEMBL14552192 | 0.90 | CTSL (0.52) | CTSLCTSSCTSKCTSHIL23R | |
| SCHEMBL14552191 | 0.89 | CTSL (0.60) | CTSLCTSSCTSKCTSHIL23R | |
| SCHEMBL14552142 | 0.86 | IL23R (0.57) | IL23RMC4R | |
| SCHEMBL30004418 | 0.85 | IL23R (0.58) | IL23R | |
| SCHEMBL23660906 | 0.85 | CTSL (0.65) | CTSLCTSSCTSKCTSHIL23R | |
| SCHEMBL23660890 | 0.85 | CTSL (0.65) | CTSLCTSSCTSKCTSHIL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012432-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012432-A1 | Peptides for Treatment of Obesity | MC4R, GIPR, MC3R | CTSL 717/4885CTSS 1180/4885CTSK 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.